Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bites and Stings × Lidocaine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13 Neoplasms 12 Pain 11 Colorectal Neoplasms 11 Pain, Postoperative 9 Prostatic Neoplasms 7 Lung Neoplasms 7 Cancer Pain 5 Agnosia 5 Neuralgia 4 Keratosis, Actinic 4 Head and Neck Neoplasms 4 Colonic Neoplasms 4 Liver Neoplasms 3 Chronic Pain 3 Stomatitis 2 Stomach Neoplasms 2 Recurrence 2 Pilonidal Sinus 2 Oropharyngeal Neoplasms 2 Myofibroma 2 Mucositis 2 Leiomyoma 2 Ileus 2 Carcinoma, Non-Small-Cell Lung 2 Wounds and Injuries 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Tuberculosis 1 Thyroid Neoplasms 1

Interventions

pembrolizumab 3 enzalutamide 2 blinatumomab 2 abiraterone 2 Stents 2 Immune Checkpoint Inhibitors 2 Cytochrome P-450 Enzyme System 2 soybean oil, phospholipid emulsion 1 durvalumab 1 dostarlimab 1 cemiplimab 1 camrelizumab 1 atezolizumab 1 Surgical Procedures, Operative 1 Surgical Instruments 1 Radiotherapy, Conformal 1 Radiotherapy 1 Passive Cutaneous Anaphylaxis 1 Palliative Care 1 Nephrotomy 1 Nephrostomy, Percutaneous 1 Neoadjuvant Therapy 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Morphine 1 Lidocaine 1 Levobupivacaine 1 Immunotherapy 1 Hydroxyurea 1 Etoposide 1 Etanercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02121951 2018-04-10

QLB

National Cancer Institute, Egypt

Phase 4 Withdrawn

Bites and Stings, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡